Magtrace
PreclinicalSmall molecule
Magtrace is one of 6 small molecule programs targeting Vulvar Cancer. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
5 competitors in Vulvar Cancer
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 2
Lenvima
EisaiPhase 2
Blenoxane
Bristol-Myers SquibbPhase 2
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 2
Paraplatin
AAvyxa
Phase 2
Magtrace
SSahlgrenska University Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Magtrace. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- SSahlgrenska University Hospital